Skip to main content
SpringerLink
Log in

Ketamine

From Abused Drug to Rapid-Acting Antidepressant

  • Book
  • © 2020

Overview

Editors:
  1. Kenji Hashimoto

    1. Division of Clinical Neuroscience, Chiba University, Chiba, Japan

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. Soichiro Ide

    1. Tokyo Metropolitan Institute of Medical, Tokyo, Japan

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  3. Kazutaka Ikeda

    1. Tokyo Metropolitan Institute of Medical, Tokyo, Japan

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  • Presents basic research data and clinical trial results supporting ketamine’s effectiveness as treatment for depression

  • Discusses advances in understanding of mechanisms of action

  • Examines evidence on ketamine abuse and countermeasures

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (11 chapters)

  1. Front Matter

    Pages i-v
    Download chapter PDF

  2. Ketamine Abuse: Past and Present

    • Ming-Chyi Huang, Shih-Ku Lin
    Pages 1-14

  3. Brain Imaging of Ketamine Abusers

    • Yanhui Liao, Wei Hao
    Pages 15-31

  4. Management of Complications of Ketamine Abuse

    • Steffi K. K. Yuen, Anthony C. F. Ng
    Pages 33-46

  5. Site of Ketamine Action on the NMDA Receptor

    • Hisashi Mori
    Pages 47-67

  6. Synaptic Modulation in the Effect of Ketamine

    • Daisuke Okada
    Pages 69-87

  7. Behavioral Pharmacology of Ketamine: An Overview of Preclinical Studies

    • Naoyuki Hironaka
    Pages 89-103

  8. Antidepressant Actions of Ketamine and Its Two Enantiomers

    • Lijia Chang, Yan Wei, Kenji Hashimoto
    Pages 105-125

  9. The Role of Gut Microbiota in the Antidepressant Effects of Ketamine

    • Yue Wang, Xiaolin Xu, Ailin Luo, Chun Yang
    Pages 127-141

  10. Effects of Ketamine on Pain and Depression Comorbidity

    • Xiao-Hui Tang, Jian-Jun Yang
    Pages 143-156

  11. Distinct Roles of NMDA Receptor GluN2 Subunits in the Effects of Ketamine and Its Enantiomers

    • Soichiro Ide, Kazutaka Ikeda
    Pages 157-173

  12. Effects of Adjunctive Ketamine Intravenous Infusion in Taiwanese Patients with Treatment-Resistant Depression: Antidepression, Antisuicidality, BDNF Val66Met, and Brain Imaging

    • Mu-Hong Chen, Tung-Ping Su
    Pages 175-189
Back to top

Keywords

About this book

This book presents the latest data from basic research and clinical trials supporting the effectiveness of ketamine as a treatment for depression, bipolar disorder, and suicidal behavior, setting these positive findings within the context of the serious problem of ketamine abuse. The first part of the book focuses on the evidence regarding ketamine abuse, with specific reference to Asian countries, and discusses countermeasures and complication management. It then addresses the mechanisms underlying the antidepressant and side effects of ketamine, which have remained elusive, describing and discussing important new research findings. Further, it explains insights gained from whole brain imaging in rodents and from behavioral pharmacology, and presents evidence regarding the role of gut microbiota, the NMDA receptor GluN2D subunit, and the lateral habenula in the actions of ketamine. These advances form the basis for the safer use of ketamine in patients with treatment-resistant depression and are expected to lead to the development of new antidepressants.

Reviews


Editors and Affiliations

  • Division of Clinical Neuroscience, Chiba University, Chiba, Japan

    Kenji Hashimoto

  • Tokyo Metropolitan Institute of Medical, Tokyo, Japan

    Soichiro Ide, Kazutaka Ikeda

About the editors

Kenji Hashimoto, Chiba University, Chiba, Japan Dr. Hashimoto is a Professor and Vice-Director of the Center for Forensic Mental Health at Chiba University. He holds a PhD from the Faculty of Pharmaceutical Sciences at Kyushu University. After working at Fukuyama University, NIH/NIDA (Baltimore, MD) and a pharmaceutical company, he moved to Chiba University Graduate School of Medicine, where he works on the development of novel therapeutic drugs for psychiatric and neurological disorders. Dr. Hashimoto has published more than 500 articles in PubMed listed publications. 

Soichiro Ide, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan Dr. Ide is a Chief Researcher in the Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science. He holds a PhD from the Graduate School and Faculty of Pharmaceutical Sciences at Kyoto University. Dr. Ide taught and undertook research research at Hiroshima International University and Hokkaido University, before moving to his current laboratory. He is currently conducting neuropsychopharmacological research using behavioral pharmacological techniques on topics such as pain, depression, and stress. Dr. Ide has published 60 papers in PubMed listed publications.

Kazutaka Ikeda, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan Dr. Ikeda is Project Leader of the Addictive Substance Project and Chair of the Department of Psychiatry and Behavioral Sciences, Tokyo Metropolitan Institute of Medical Science. He graduated from the Faculty of Engineering at The University of Tokyo, and holds a Master’s degree from Osaka University and a PhD from Niigata University. Dr. Ikeda has worked at RIKEN, Tokyo Metropolitan Institute of Psychiatry, and was President of the Japanese Society of Neuropsychopharmacology and of the Asian College of Neuropsychopharmacology. His research focuses on neuropsychopharmacology, especially for addiction, pain, neurodevelopmental disorders, schizophrenia and depression. He has published more than 180 articles in PubMed listed publications.

Bibliographic Information

Publish with us

Policies and ethics

Back to top

Search

Navigation